| Literature DB >> 33468564 |
Sudha Sundar1,2, Ranjit Manchanda3, Charlie Gourley4, Angela George5, Andrew Wallace6, Janos Balega7, Sarah Williams8, Yvonne Wallis9, Richard Edmondson10, Shibani Nicum11, Jonathan Frost12, Ayoma Attygalle13, Christina Fotopoulou14, Rebecca Bowen12, Dani Bell15, Ketankumar Gajjar16, Bruce Ramsay17, Nicholas J Wood18, Sadaf Ghaem-Maghami19, Tracie Miles20, Raji Ganesan21.
Abstract
The British Gynecological Cancer Society and the British Association of Gynecological Pathologists established a multidisciplinary consensus group comprising experts in surgical gynecological oncology, medical oncology, genetics, and laboratory science, and clinical nurse specialists to identify the optimal pathways to BRCA germline and tumor testing in patients with ovarian cancer in routine clinical practice. In particular, the group explored models of consent, quality standards identified at pathology laboratories, and experience and data from pioneering cancer centers. The group liaised with representatives from ovarian cancer charities to also identify patient perspectives that would be important to implementation. Recommendations from these consensus group deliberations are presented in this manuscript. © IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: BRCA1 protein; BRCA2 protein; fallopian tube neoplasms; ovarian neoplasms
Mesh：
Substances：
Year: 2021 PMID： 33468564 DOI： 10.1136/ijgc-2020-002112
Source DB: PubMed Journal: Int J Gynecol Cancer ISSN： 1048-891X Impact factor: 3.437